RT Journal Article
SR Electronic
T1 SARS-CoV-2 infection fatality risk in a nationwide seroepidemiological study
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.08.06.20169722
DO 10.1101/2020.08.06.20169722
A1 Pastor-Barriuso, Roberto
A1 Pérez-Gómez, Beatriz
A1 Hernán, Miguel A.
A1 Pérez-Olmeda, Mayte
A1 Yotti, Raquel
A1 Oteo, Jesús
A1 Sanmartín, Jose L
A1 León-Gómez, Inmaculada
A1 Fernández-García, Aurora
A1 Fernández-Navarro, Pablo
A1 Cruz, Israel
A1 Martín, Mariano
A1 Delgado-Sanz, Concha
A1 de Larrea, Nerea Fernández
A1 Paniagua, Jose León
A1 Muñoz-Montalvo, Juan F.
A1 Blanco, Faustino
A1 Larrauri, Amparo
A1 Pollán, Marina
A1 ,
YR 2020
UL http://medrxiv.org/content/early/2020/08/07/2020.08.06.20169722.abstract
AB The magnitude of the infection fatality risk (IFR) of SARS-CoV-2 remains under debate. Because the IFR is the number of deaths divided by the number of infected, serological studies are needed to identify asymptomatic and mild cases. Also, because ascertainment of deaths attributable to COVID-19 is often incomplete, the calculation of the IFR needs to be complemented with data on excess mortality. We used data from a nation-wide seroepidemiological study and two sources of mortality information—deaths among laboratory-confirmed COVID-19 cases and excess deaths—to estimate the range of IFR, both overall and by age and sex, in Spain.The overall IFR ranged between 1.1% and 1.4% in men and 0.58% to 0.77% in women. The IFR increased sharply after age 50, ranging between 11.6% and 16.4% in men ≥80 years and between 4.6% and 6.5% in women ≥80 years. Our IFR estimates for SARS-CoV-2 are substantially greater than IFR estimators for seasonal influenza, justifying the implementation of special public health measures.Competing Interest StatementThe authors have declared no competing interest.Funding StatementENE-COVID study was funded by Spanish Ministry of Health, Institute of Health Carlos III & Spanish National Health System.No other external funding was received.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Institutional Review Board of the Institute of Health Carlos III (Register number: PI 39_2020)All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe manuscript includes all figures needed to replicate the IFR estimations and indicate the sources used. ENE-COVID seroprevalence figures are provided here for all sex and age groups. Data on deaths come from RENAVE and MoMo, two Spanish National Surveillance Systems. Anonymized data from these systems are available under request. The specific formulary for this purpose is provided by the Department of Communicable Diseases at the National Center for Epidemiology. Instituto de Salud Carlos III. C/ Monforte de Lemos 5 28029 Madrid. (e-mail: vigilancia.cne@isciii.es and mortalidad@isciii.es respectively). Population figures have been provided by the National Institute of Statistics and are publicly available at their website (www.ine.es). https://www.ine.es/ https://portalcne.isciii.es/enecovid19/ https://momo.isciii.es/public/momo/dashboard/momo_dashboard.html https://cnecovid.isciii.es/covid19/